Valeant Pharmaceuticals International, Inc.NYSE
Valeant: 70% Downside And Shocking New Information To Explain The Drug Price Increases And Subpoena
Adam Stockmeister • 55 Comments
Adam Stockmeister • 55 Comments
The Emperor Is 25% To 65% Naked: Valeant, Salix, And Cash EPS
Dorsia Capital • 13 Comments
Dorsia Capital • 13 Comments
Wed, Nov. 30, 11:47 AM
- The Financial Time reports that Takeda Pharmaceutical (OTCPK:TKPHF) lost its patience with Valeant Pharmaceuticals (VRX -7.9%) over its alleged inability to provide key information about Salix. A person close to the matter said the negotiations suffered because Valeant was unable to provide enough information about Salix's business and financials due to all the distractions and disruptions Valeant has endured over the past year.
- Another source said the potential deal still has legs if Valeant can get its act together and deliver the information.
- Takeda declined to comment on the situation while Valeant could not be immediately reached for comment.
Wed, Nov. 30, 10:37 AM
- The woes continue for Valeant Pharmaceuticals (VRX -8.3%). According to the WSJ, negotiations with Takeda Pharmaceutical (OTCPK:TKPHF) over the $10B sale of Salix Pharmaceuticals have broken down due to last-minute disagreements.
- Valeant is reportedly moving ahead with plans to build a direct sales force to promote Xifaxan (rifaximin). It acquired Salix in 2015 for $14.5B.
Wed, Nov. 2, 10:51 AM
- Nano cap Palatin Technologies (PTN +5.3%) spiked almost 55% before retracing on the news that it is exploring a possible sale. It has retained Greenhill & Co. to advise after receiving multiple offers from interested suitors.
- Palatin's lead product candidate is bremelanotide, in development for the on-demand treatment of female sexual dysfunction in premenopausal women with hypoactive sexual desire disorder (HSDD). Its key advantage over Valeant Pharmaceuticals' (VRX -8.2%) Addyi (filbanserin) is that women who have consumed alcohol can use it.
- Valeant bought the company that developed Addyi, Sprout Pharmaceuticals, for $1B but the drug has struggled to gain traction due to, in large part, its contraindication with alcohol because of the risk of fainting.
Tue, Nov. 1, 3:41 PM
- Battered and bruised Valeant Pharmaceuticals (VRX +16.3%) shows some life. Shares are up on increased volume in response to the news that the company is in talks to sell its Salix unit to Takeda (OTCPK:TKPHF)(OTCPK:TKPYY) for $10B.
- Valeant bought Salix last year for $158 per share which valued Salix at $14.5B at the time.
- If the transaction goes through, it will go a long way towards easing Valeant's $30B debt burden.
- Update: In a statement, Valeant confirms that it is in discussions with third parties related to certain divestitures including, but not limited to, Salix.
Thu, Jun. 9, 7:09 AM
- Jaguar Animal Health (NASDAQ:JAGX) enters into a $15M 30-month common stock purchase agreement with Aspire Capital Fund, LLC. Upon the execution of the contract, Aspire bought 222,222 shares for $500K ($2.25/share). Remaining shares will be purchased at prevailing market prices.
- The company and Napo Pharmaceuticals are involved in exploratory discussions about a possible merger and/or other ways to work together to build their businesses. Napo currently owns 26.3% of Jaguar common shares. Last month, it assumed ownership of the New Drug Application (NDA) and responsibility for human applications of crofelemer from Valeant Pharmaceuticals (NYSE:VRX) who acquired the rights from Salix Pharmaceuticals in April.
- The FDA approved crofelemer, branded as Fulyzaq, in December 2012 for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on retroviral therapy.
- JAGX closed yesterday at $1.32.
Dec. 8, 2015, 2:24 AM
- Valeant Pharmaceuticals (NYSE:VRX) is considering selling its gas permeable contact lens division, Paragon Vision Sciences, that has come under scrutiny by the Federal Trade Commission for monopoly concerns.
- The probe is one of several reviews of the company, which is being investigated by lawmakers over steep price increases and from investors over its relationship with specialty pharmacy Philidor.
- Valeant shares have dropped more than 60% since it came under criticism for drug price hikes in September.
Oct. 15, 2015, 9:38 AM
- Valeant Pharmaceuticals (VRX -9.2%) completes its purchase of all outstanding shares of Synergetics USA (NASDAQ:SURG) at a price of $6.50 per share, net of cash, plus one contingent value right (CVR) per share.
- Each CVR represents the right to receive up to two contingent payments (up to an aggregate of $1.00) upon the achievement of certain milestones.
- Previously: Valeant buys Synergetics USA for $6.50 in cash (Sept. 2)
Sep. 2, 2015, 9:23 AM
- Thinly traded micro cap Synergetics USA (NASDAQ:SURG) jumps 53% premarket on increased volume on the news that Valeant Pharmaceuticals (NYSE:VRX) will acquire it for $6.50 per share in cash. SURG shareholders will receive an additional $1.00 per share in cash if certain sales milestones are achieved after the transaction closes in Q4.
- Synergetics develops and markets surgical devices, including the VersaVIT 2.0 for vitrectomy (eye surgery) and the Directional II Laser Probe.
Aug. 20, 2015, 11:31 AM
- In news everyone should know by now, Valeant Pharmaceuticals (VRX -3.3%) acquires privately-held Sprout Pharmaceuticals for $1B in cash. Sprout's "Viagra for women," Addyi (flibanserin) was approved two days ago by the FDA for the treatment of hypoactive sexual desire in premenopausal women. The commercial launch will commence in Q4. Because of the product's Boxed Warning, doctors and pharmacies will need to be certified under the FDA's REMS program to assure safe use.
- Sprout CEO Cindy Whitehead will report to Valeant EVP and Group Chairman Anne Whitaker.
- Previously: FDA clears "Viagra for women" (Aug. 18)
Aug. 20, 2015, 9:02 AM
- Valeant Pharmaceuticals' (NYSE:VRX) $1B takeout of privately-held Sprout Pharmaceuticals is stoking speculation that potential competitor Palatin Technologies (NYSEMKT:PTN) is an attractive acquisition target as well.
- Palatin's candidate for the treatment of female sexual dysfunction, including hypoactive sexual desire disorder (HSDD), is bremelanotide, a synthetic peptide analog of the naturally occurring hormone alpha-MSH, a melanocortin agonist. The melanocortin system plays a key role in sexual function as well as pigmentation, inflammation and energy homeostasis.
- A recently completed Phase 2b clinical trial met its primary endpoint of a statistically significant increase in satisfying sexual events compared to placebo. Two Phase 3 studies are underway, each estimated to be completed in mid-2017.
- Bremelanotide's big advantage over Sprout's flibanserin is the avoidance of hypotension and syncope (temporary loss of consciousness) when combined with alcohol. The most common adverse events observed with bremelanotide in the Phase 2b study were facial flushing (~17% of the participants), nausea (18 - 25%, depending of the dose) and headache (9 - 15%, depending on the dose).
Jul. 23, 2015, 3:50 PM
Jul. 17, 2015, 9:18 AM
- Valeant Pharmaceuticals (NYSE:VRX) acquires Mercury Holdings, the holding company of Amoun Pharmaceutical, for $800M plus contingent payments. Amoun is the largest Egyptian pharma firm, expected to book sales of EGP1.75B ($227.5M) this year. It specializes in anti-hypertensives, broad spectrum antibiotics and anti-diarrheals.
- Valeant intends to use Amoun as a platform for further expansion into the Middle East and North Africa pharmaceutical markets. The transaction should close in Q3.
Jun. 26, 2015, 11:04 AM| Jun. 26, 2015, 11:04 AM | 18 Comments
Jun. 25, 2015, 4:07 PM
May 29, 2015, 12:19 PM
- Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) current #5 rank in the global animal health market could change once it divests its low margin plastics business either via an IPO or direct sale, possibly to a private equity firm. Analysts believe the unit could fetch as much as 11B euros ($12.1B).
- CEO Marijn Dekkers says animal health is a "very attractive business for us. We've always looked with interest in it. It hasn't happened with us yet."
- The top acquisition target would be Zoetis (ZTS +0.8%) which generated $4.8B in sales in 2014. Bayer will probably have competition, though. Valeant Pharmaceuticals (VRX -1.7%) and Merck (MRK +0.2%) have been mentioned as likely suitors.
Mar. 27, 2015, 4:16 PM
- Brean Capital's Difei Yang says small cap Hyperion Therapeutics (NASDAQ:HPTX) should be on the acquisition radar considering Big Pharma's appetite for rare disease players. The company's revenues are generated by two products, Ravicti (glycerol phenylbutyrate) and Buphenyl (sodium phenylbutyrate), that treat urea cycle disorders, inherited metabolic diseases caused by a deficiency in one of the enzymes or transporters in the urea cycle. Elevated ammonia, a consequence of the failure to convert ammonia to urea, can have serious consequences, such as brain damage, coma and even death.
- Mr. Yang estimates that the company's takeout price at $60 per share. He lists Shire plc (NASDAQ:SHPG), Valeant Pharmaceuticals (NYSE:VRX), and Endo International (NASDAQ:ENDP) as potential suitors. HPTX closed today at just under $43.
- The company booked ~$114M in revenues last year but took a loss of ($6.3M).